CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine

Author:

Siskind Dan12345ORCID,Russell Anthony W.36,Suetani Shuichi2457,Flaws Dylan38,Kisely Steve234,Moudgil Vikas8,Northwood Korinne23,Robinson Gail89,Scott James G.4810,Stedman Terry11,Warren Nicola234,Winckel Karl1213,Cosgrove Peter411,Baker Andrea411

Affiliation:

1. School of Clinical Medicine, The University of Queensland, c/- MIRT, Level 2 Mental Health, 228 Logan Rd, Woolloongabba, Brisbane, QLD 4102, Australia

2. Metro South Addiction and Mental Health Services, Brisbane, QLD, Australia

3. School of Clinical Medicine, The University of Queensland, Brisbane, QLD, Australia

4. Queensland Centre for Mental Health Research, Brisbane, QLD, Australia

5. Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia

6. Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia

7. Medical School, Griffith University, Brisbane, QLD, Australia

8. Metro North Mental Health Services, Brisbane, QLD, Australia

9. Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, Australia

10. QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

11. West Moreton Mental Health Service, Brisbane, QLD, Australia

12. Department of Pharmacy, Princess Alexandra Hospital, Brisbane, QLD, Australia

13. School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia

Abstract

Background: There is limited evidence on interventions to minimise weight gain at clozapine commencement. We compared the effect of adjunctive metformin versus placebo at clozapine initiation. Methods: People with schizophrenia commencing on clozapine were randomised to either metformin or placebo for 24 weeks. The primary outcome was difference in the change of body weight. Secondary outcomes included comparative rates of weight gain of more than 5%, overall weight gain/loss, and differences in metabolic and psychosis outcomes. Results: The study was closed prematurely in March 2020 due to COVID-19 restrictions. Ten participants were randomised to each of the metformin and placebo groups. Eight metformin group and five placebo group participants completed the trial and were included in the analysis. The study was insufficiently powered to detect difference between the metformin and placebo groups for the primary outcome of change in weight (0.09 kg vs 2.88 kg, p = 0.231). In terms of secondary outcomes, people in the metformin group were significantly less likely to gain >5% of their body weight (12.5% vs 80%, p = 0.015) and were more likely to lose weight (37.5% vs 0% p = 0.024) compared to placebo. There was no difference between the groups in terms of adverse drug reactions (ADRs). Conclusion: While limited by the forced premature closure of the trial due to COVID19, the findings from this randomised controlled trial are promising. Clozapine and metformin co-commencement may be a promising treatment to prevent clozapine-associated weight gain, especially given the low rates of ADRs associated with metformin. This supports the consideration of use of metformin to prevent weight gain in people initiated on clozapine; however, further studies are needed to confirm this finding. Trial registration: ACTRN12617001547336

Publisher

SAGE Publications

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Psychology (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3